These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24523507)

  • 1. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.
    Zhang Q; Wang HY; Wei F; Liu X; Paterson JC; Roy D; Mihova D; Woetmann A; Ptasznik A; Odum N; Schuster SJ; Marafioti T; Riley JL; Wasik MA
    J Immunol; 2014 Mar; 192(6):2913-9. PubMed ID: 24523507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
    Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
    Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
    Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
    Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
    Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
    J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
    Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
    Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
    Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
    Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
    Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
    J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
    Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
    Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes.
    Shatrova AN; Mityushova EV; Vassilieva IO; Aksenov ND; Zenin VV; Nikolsky NN; Marakhova II
    PLoS One; 2016; 11(12):e0167215. PubMed ID: 27936140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.
    Nagy ZS; LeBaron MJ; Ross JA; Mitra A; Rui H; Kirken RA
    Mol Cancer; 2009 Aug; 8():67. PubMed ID: 19709433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple negative feedbacks on CD152 expression in allograft tolerance.
    Tsai MK; Ho HN; Chien HF; Tzeng MC; Chen CH; Lee PH
    Transplantation; 2005 Jan; 79(2):174-81. PubMed ID: 15665765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
    Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
    PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
    Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
    Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.